Stemline Therapeutics reported U$169070 in Current Assets for its first quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Abbvie U$ 21256M 30502M
Agenus U$ 104.759M 1.985M
Amgen U$ 22895M 4082M
Biocryst Pharmaceuticals U$ 203M 78M
Bristol Myers Squibb U$ 34343M 2490M
Celldex Therapeutics U$ 208M 153M
Daiichi Sankyo Y 1317804M 66315M
Eisai Y 501247M 20158M
Geron U$ 220M 86M
GlaxoSmithKline 2297800000 95500000
Halozyme Therapeutics U$ 500.358M 32.387M
JAZZ PHA U$ 2555.573M 253.227M
Macrogenics 260196000 64911000
Merk U$ 29343M 3169M
Novartis 23882000000 784000000
Pfizer U$ 46424M 11686M
Seattle Genetics U$ 1330.582M 170.135M
Stemline Therapeutics U$ 169M 16M
Sumitomo Dainippon Y 353479M 10611M
United Therapeutics U$ 1894.4M 48.1M
Verastem U$ 144M 4M